Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BMS Halts Development of Diabetes Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

BMS Halts Development of Diabetes Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb has discontinued the development of muraglitazar, a dual alpha/gamma PPAR (peroxisome proliferator-activated receptor) agonist in development for type 2 diabetes and will focus its efforts on other priority portfolio projects.

On October 18, 2005, the FDA issued an approvable letter for muraglitazar requesting additional information on the drug’s cardiovascular safety profile. Since that time, the company has continued to further its understanding of the compound. This included additional analyses of existing studies with muraglitazar, results of outcomes studies with other PPAR alpha and gamma agonists, and the evaluation of the cardiovascular safety results from a recently completed muraglitazar study. Based on these accumulated data, the company contends that a long-term trial is needed. BMS’s commercial evaluation of other diabetes alternatives likely to be available in five years, as well as consideration of competing development opportunities in the company’s portfolio, led it to discontinue the compound’s development.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters